Concepedia

Publication | Open Access

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma

DOIFull Paper Access

606

Citations

35

References

2023

Year

Ingo K. Mellinghoff, Martin J. van den Bent, Deborah T. Blumenthal, Mehdi Touat, Katherine B. Peters, Jennifer Clarke, Joe Mendez, Shlomit Yust‐Katz, Liam Welsh, Warren Mason,
New England Journal of Medicine

Abstract

In patients with grade 2 IDH-mutant glioma, vorasidenib significantly improved progression-free survival and delayed the time to the next intervention. (Funded by Servier; INDIGO ClinicalTrials.gov number, NCT04164901.).

References

YearCitations

Page 1